索磷布韦维帕他韦片联合低剂量利巴韦林治疗丙肝的疗效观察

Observation of Efficacy of Sofosbuvir and Velpatasvir Tablets Combined with Low-Dose Ribavirin in Hepatitis C

目的观察索磷布韦维帕他韦片联合低剂量利巴韦林治疗丙肝的疗效。方法选取2020年1月至2022年1月前往濮阳市疾病预防控制中心门诊部就诊的60例丙肝患者为研究对象,利用随机数字表法分为两组各30例。对照组采取索磷布韦维帕他韦片治疗,观察组采取索磷布韦维帕他韦片联合低剂量利巴韦林治疗,12周后比较两组病毒学应答率(快速病毒学应答率、早期病毒学应答率、治疗终点病毒学应答率、持续病毒学应答率)、肝功能指标(谷草转氨酶、谷丙转氨酶、胆红素)、不良反应(肌肉疼痛、乏力、皮疹)发生率差异。结果观察组的快速病毒学应答率90.00%、早期病毒学应答率93.33%、治疗终点病毒学应答率90.00%、持续病毒学应答率96.67%、肌肉疼痛发生率6.67%、乏力发生率3.33%、皮疹发生率3.33%,与对照组的86.67%、90.00%、90.00%、96.67%、3.33%、3.33%、3.33%比较,差异无统计学意义(P>0.05);治疗前两组患者的肝功能指标比较,差异无统计学意义(P>0.05),治疗后均低于各组治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论在丙肝治疗中索磷布韦维帕他韦片联合低剂量利巴韦林并不能够较索磷布韦维帕他韦片单独使用进一步提高病毒学应答率,但却可以强化肝功能改善效果且不良反应发生率低。

Objective To observe the efficacy of sofosbuvir and velpatasvir tablets combined with low-dose ribavirin in the treatment of hepatitis C.Methods A total of 60 hepatitis C patients who went to the outpatient department of Puyang Center for Disease Control and Prevention from January 2020 to January 2022 were selected as the research objects,and divided into two groups with 30 cases in each group by random number table method.The control group was treated with sofosbuvir and velpatasvir tablets,while the observation group was treated with sofosbuvir and velpatasvir tablets combined with low-dose ribavirin.After 12 weeks,the virological response rate(rapid virological response rate,early virological response rate,treatment endpoint virological response rate,and sustained virological response rate),liver function indicators(aspartate aminotransferase,alanine aminotransferase,total bilirubin),adverse reactions(muscle pain,fatigue,rash)occurrence rate difference were compared between the two groups.Results The rapid virological response rate of the observation group was 90.00%,the early virological response rate was 93.33%,the end-point virological response rate was 90.00%,the sustained virological response rate was 96.67%,the incidence of muscle pain was 6.67%,and the incidence of fatigue was 3.33%.The incidence of rash was 3.33%,compared with 86.67%,90.00%,90.00%,96.67%,3.33%,3.33%,and 3.33%of the control group,and the difference was not statistically significant(P>0.05).There was no significant difference in liver functional indexes between two groups before treatment(P>0.05),after treatment the liver functional indexes were lower than before treatment,and the observation group were lower than the control group,with a statistically significant difference(P<0.05).Conclusion Sofosbuvir and velpatasvir tablets combined with low-dose ribavirin in the treatment of hepatitis C cannot further improve the virological response rate compared with sofosbuvir and velpatasvir tablets alone,but can enhance the liver function,and the incidence of adverse reactions were low.